Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Pluristem Therapeutc (PSTI)

Pluristem Therapeutc (PSTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,574
  • Shares Outstanding, K 32,005
  • Annual Sales, $ 20 K
  • Annual Income, $ -29,150 K
  • 60-Month Beta 2.31
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.48
Trade PSTI with:

Options Overview Details

View History
  • Implied Volatility 89.61%
  • Historical Volatility 45.66%
  • IV Percentile 5%
  • IV Rank 15.46%
  • IV High 177.05% on 03/29/21
  • IV Low 73.62% on 09/17/21
  • Put/Call Vol Ratio 0.04
  • Today's Volume 118
  • Volume Avg (30-Day) 326
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 2,690
  • Open Int (30-Day) 4,555

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.37
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.44
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +0.71%
on 09/24/21
3.22 -12.11%
on 09/03/21
-0.24 (-7.82%)
since 08/24/21
3-Month
2.81 +0.71%
on 09/24/21
4.21 -32.78%
on 06/28/21
-1.25 (-30.64%)
since 06/24/21
52-Week
2.81 +0.71%
on 09/24/21
11.85 -76.12%
on 12/08/20
-6.07 (-68.20%)
since 09/24/20

Most Recent Stories

More News
Pluristem CEO Issues Shareholder Update

Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.

PSTI : 2.83 (-5.98%)
Hematopoietic Stem Cell Transplant Market Analysis By Industry Growth, Size, Share, Demand, Trends and Research Report 2029

Research Nester released a report titled "" which delivers a detailed overview of the hematopoietic stem cell transplant market in terms of market segmentation by transplant type, disease indication, application,...

RGBP : 0.0360 (-15.49%)
THMO : 2.10 (-3.67%)
PSTI : 2.83 (-5.98%)
CO : 4.61 (+0.88%)
Innocan Pharma gained 350% in value this year Is it still a good time to buy? | BreezyScroll

Prospective investors should know that this is just the beginning, as according to financial analysts, InnoCan's stock surged due to the publication of its recent experimental trials. The exposure bolstered...

INNO.CN : 1.000 (+1.01%)
INNPF : 0.8100 (-6.24%)
TEVA : 8.95 (-1.10%)
PSTI : 2.83 (-5.98%)
BCLI : 3.37 (-1.46%)
InnoCan Pharma receives strong buy recommendation: Here is why

Those who invested in InnoCan Pharma's (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) a year ago are up 273%.

INNO.CN : 1.000 (+1.01%)
INNPF : 0.8100 (-6.24%)
TEVA : 8.95 (-1.10%)
PSTI : 2.83 (-5.98%)
BCLI : 3.37 (-1.46%)
Worldwide Hematopoietic Stem Cell Transplantation Industry to 2027 - Featuring Pluristem Therapeutics, CellGenix and Regen Biopharma Among Others

/PRNewswire/ -- The report has been added to offering.

PSTI : 2.83 (-5.98%)
Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

PluristemTherapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor...

PSTI : 2.83 (-5.98%)
INTL : 55.63 (+1.16%)
ICCM : 9.85 (-2.01%)
CTGL : 0.0500 (unch)
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

-- Topline results are expected during the fourth quarter of 2021

PSTI : 2.83 (-5.98%)
Preeclampsia Therapeutics Market 2021-2028 | Size, Share, Growth, Trends, Analysis, Competitive Landscape, Revenue, Forecast Report

Increasing spread of preeclampsia worldwide will be the key driver of the global preeclampsia therapeutics market growth during the forecast period. Preeclampsia refers to a condition wherein a woman experiences...

AMAG : 13.75 (+0.15%)
PKI : 182.88 (-1.72%)
PSTI : 2.83 (-5.98%)
Pluristem to Receive EUR20M Non-Dilutive Funding from the European Investment Bank

PluristemTherapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the "Company"), a leading biotechnology company, today announced the receipt of a "Disbursement Offer" in the amount of EUR20 million (approximately...

PSTI : 2.83 (-5.98%)
Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE: PSTI), a leading regenerative medicine company, today reported positive topline results in its first study to evaluate the safety and exploratory efficacy...

PSTI : 2.83 (-5.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use,...

See More

Key Turning Points

3rd Resistance Point 3.27
2nd Resistance Point 3.18
1st Resistance Point 3.00
Last Price 2.83
1st Support Level 2.73
2nd Support Level 2.64
3rd Support Level 2.46

See More

52-Week High 11.85
Fibonacci 61.8% 8.40
Fibonacci 50% 7.33
Fibonacci 38.2% 6.26
Last Price 2.83
52-Week Low 2.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar